Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07778277
Starting soon Not applicable

Personalized Sensory Stimulation: Urban and Rural Dementia Care

NCT07778277 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Not applicable
Started
2026-09-20
Last updated
2026-08-21

Condition(s) studied

DementiaAcoustic StimulationHealthcare DisparitiesPrecision MedicineCognitive Training

Investigational drug(s) / intervention(s)

Digital personalized intervention system (active setting)Gamma auditory stimulation device (active setting)Gamma auditory stimulation device (sham setting)

Digital personalized intervention system (active setting): Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) during cognitive training activity for 1 hour per day, 2 days a week, over 12 weeks, for a total of 24 hours.

Gamma auditory stimulation device (active setting): Participants will receive auditory stimulation using the gamma auditory stimulation device (active setting) during cognitive training activity for 1 hour per day, 2 days a week, over 12 weeks, for a total of 24 hours.

Gamma auditory stimulation device (sham setting): Participants will receive auditory stimulation using the gamma auditory stimulation device (sham setting) during cognitive training activity for 1 hour per day, 2 days a week, over 12 weeks, for a total of 24 hours.

Study summary

As Taiwan transitions into a super-aged society, rising dementia rates have severely strained long-term care systems. Although current daycare centers provide multi-modal programs, they remain limited to behavioral training, lacking precise interventions targeting brain function and neuroplasticity or integrated non-invasive neuromodulation technologies. Furthermore, urban-rural disparities in resources, staffing allocation, and tech experience hinder practical deployment, with empirical research remaining scarce. Addressing this gap, this study investigates a smart brain health promotion model combining personalized gamma music stimulation and cognitive training for mild cognitive impairment and dementia, while evaluating its feasibility across diverse care settings.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged ≥ 60 years * The score of MoCA between 10 to 25 Exclusion Criteria: * Diagnosis of other psychiatric or neurological disorders, and those with a history of neurological or psychiatric disorders that may affect cognitive assessment or performance. For example (but not limited to): Parkinson's disease, schizophrenia, major depressive disorder, epilepsy, severe traumatic brain injury with loss of consciousness, and stroke. * Drug, Nicotine or alcohol addictions * Serious heart, liver or kidney disorders, and visual, auditory or motor impairments interfering with neuropsychological tests.

Primary outcome measure(s)

  • Change score of Montreal Cognitive Assessment (MoCA) — baseline (T1), through intervention completion, an average of 3 month (T2)
    This scale is one of the most commonly used tools for assessing mild cognitive impairment and early-stage dementia, evaluating capacities such as executive function, attention, visuospatial abilities, language, memory, and orientation. The scale has a maximum score of 30, with higher scores indicating better cognitive function.

Trial sites (1)

FacilityCityRegionStatus
Chang Gung University Taoyuan Guishan

More Chang Gung Memorial Hospital trials in Taiwan

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Recruiting
Fractional Exhaled Nitric Oxide and Exacerbations of COPD Starting soon
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores Recruiting
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma Active, not recruiting
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Recruiting

Other trials for the same condition

Far-Infrared Therapy for the Effect of Alzheimer Disease Dementia Recruiting
Effects of Jing Si Herbal Tea on Quality of Life and Sleep in Dementia and Their Caregivers Recruiting
Taiwan Post-Stroke Disability Study Recruiting
NMDA Enhancement Combined With Omega-3 for Early Dementia Starting soon
Research on the Early and Prognosis Diagnosis of Vascular Dementia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07778277 on ClinicalTrials.gov ↗ ← All trials in Taiwan